Who are double-blind rifaximin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rifampin containing regimen, Avelox, Zithromax, Cipro, Rocephin, Amoxil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/double-blind-rifaximin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

double-blind rifaximin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

double-blind rifaximin (double-blind rifaximin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic. Area: Gastroenterology.

phase 3 Antibiotic RNA polymerase beta subunit Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

double-blind rifaximin (double-blind rifaximin) — Bausch Health Americas, Inc.. Rifaximin works by inhibiting bacterial RNA synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
double-blind rifaximin TARGET	double-blind rifaximin	Bausch Health Americas, Inc.	phase 3	Antibiotic	RNA polymerase beta subunit
Rifampin containing regimen	Rifampin containing regimen	Nantes University Hospital	phase 3	Bacterial RNA polymerase inhibitor	bacterial RNA polymerase beta subunit
Avelox	moxifloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Zithromax	azithromycin	Pfizer Inc.	marketed	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Rocephin	ceftriaxone	Generic (originally Roche)	marketed	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	marketed	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-12-08 — Amoxil · 8778924 · Compound · US
2026-12-08 — Amoxil · 8357394 · Formulation · US
2027-05-07 — Amoxil · 8299052 · Method of Use · US
2029-04-21 — Cipro · 9205048 · Method of Use · US
2029-04-21 — Cipro · 9603796 · Compound · US
2029-04-21 — Cipro · 11369566 · Formulation · US
2029-12-11 — Cipro · 9233068 · Formulation · US
2030-04-27 — Cipro · 8318817 · Method of Use · US
2035-07-01 — Cipro · 9220796 · Formulation · US
2037-11-12 — Cipro · 11040004 · Method of Use · US
2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (Antibiotic class)

Bausch Health Americas, Inc. · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
BioVersys AG · 1 drug in this class
Bosnalijek D.D · 1 drug in this class
Capital Medical University · 1 drug in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class
Incheon St.Mary's Hospital · 1 drug in this class
Jomaa Pharma GmbH · 1 drug in this class
King Abdulaziz University · 1 drug in this class
Menzies School of Health Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). double-blind rifaximin — Competitive Intelligence Brief. https://druglandscape.com/ci/double-blind-rifaximin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab